Researchers conducted a multicenter randomized study involving 2008 patients undergoing coronary angioplasty (PCI). In this group, 1005 patients underwent a procedure guided by OCT, and 1003 patients by IVUS. The average age of participants was 65 years, 21% of subjects were women, and there were no significant differences between both groups. The primary endpoint was<a href="https://solaci.org/en/2023/09/01/esc-2023-octivus-trial-is-oct-superior/" title="Read more" >...</a>
Cardiogenic shock (CS) represents the main cause of death in patients hospitalized for acute myocardial infarction (AMI). Despite advances in its management, mortality continues to be high, between 40-50% within the first 30 days. In an attempt to improve survival, early extracorporeal life support (ECLS) is being increasingly used to stabilized hemodynamics in cases of<a href="https://solaci.org/en/2023/08/29/esc-2023-ecls-shock-2/" title="Read more" >...</a>
The proportion of patients undergoing high risk PCI (HRPCI) is on the rise. It includes patients with different clinical, anatomical and procedural characteristics, such as low ejection fraction, severe vascular disease, three vessel or left main disease, severe lesion calcification and the use of atherectomy. Mechanical circulatory support devices (MCS) during HRPCI, such as the<a href="https://solaci.org/en/2023/07/26/are-there-sex-differences-in-plvad-assisted-high-risk-pci/" title="Read more" >...</a>
Transcatheter aortic valve implantation (TAVI) has become the standard treatment for elderly patients with severe symptomatic aortic stenosis. While this has led to the development of new devices with different features, evidence from randomized studies on these new scaffolds is limited. The randomized SCOPE I study (Safety and Efficacy of the Symetis ACURATE Neo/TF Compared<a href="https://solaci.org/en/2023/07/24/scope-i-results-at-3-years-acurate-neo-vs-sapien-3/" title="Read more" >...</a>
Reduced dosage of tenecteplase in elderly patients undergoing a pharmaco-invasive strategy. Delays in achieving timely reperfusion in patients with acute coronary syndrome with ST elevation (STEACS), whether through fibrinolysis or primary percutaneous coronary intervention (PCI), are associated with increased mortality. European guidelines establish a target reperfusion time of 120 minutes after the first medical contact<a href="https://solaci.org/en/2023/07/24/stream-2-reduced-dosage-of-tenecteplase-for-patients-over-60-years-old/" title="Read more" >...</a>
In the early days of percutaneous coronary intervention (PCI) in patients with ST elevation acute myocardial infarction (STEMI), no reflow phenomenon was known as an indicator of the worst possible outcomes in terms of left ventricular remodeling, infarct size, ejection fraction and mortality, at long term. The TOTAL study (Routine Aspiration Thrombectomy with PCI Versus<a href="https://solaci.org/en/2023/07/17/no-reflow-after-primary-pci-in-stemi-an-angiographic-analysis-of-the-total-study/" title="Read more" >...</a>
Mitral regurgitation is the most common valvular heart disease. Its cause is most frequently functional or secondary dysfunction (functional mitral regurgitation, FMR) compared with degenerative mitral regurgitation (DMR), which is associated with decreased ventricular function, hospitalization for heart failure, and mortality. While medical treatment is effective over extended periods, a significant number of patients cannot<a href="https://solaci.org/en/2023/07/10/is-edge-to-edge-treatment-with-pascal-effective-at-3-years/" title="Read more" >...</a>
Percutaneous treatment of chronic total occlusions has increase, and has become a a more habitual therapeutic challenge. However, there is limited information on distal vessel quality and its association with outcomes and techniques. This variable appears to be excluded form CTO scores, except for the RECHARGE (REgistry of CrossBoss and Hybrid procedures in FrAnce, the<a href="https://solaci.org/en/2023/07/06/relationship-between-distal-vessel-quality-and-outcomes-in-the-treatment-of-chronic-total-occlusions/" title="Read more" >...</a>
At present, transcatheter aortic valve replacement (TAVR) has become increasingly common to treat severe symptomatic aortic stenosis, with the transfemoral approach being the most common access strategy, associated to better outcomes vs. other access sites. Even though vascular complication rates (VC) have dropped given increased operation experience and improved devices, such as the use of<a href="https://solaci.org/en/2023/06/27/vasc-observant-ii-substudy-impact-of-vascular-complications-after-tavr/" title="Read more" >...</a>
In recent years, there has been an increase in the number of percutaneous coronary interventions (PCI) performed to treat chronic total occlusion (CTO). This increase is due to the availability of more advanced technology and greater experience of both operators and specialized centers. However, it is important to note that this technique is not free<a href="https://solaci.org/en/2023/06/14/frequency-and-causes-of-mortality-in-chronic-total-occlusion/" title="Read more" >...</a>